Please note, this OEL/ADE monograph also applies to retigabine dihydrochloride (CAS RN 150812-13-8). Retigabine (international nonproprietary name) or ezogabine (United States (US) adopted name) is a first-in-class antiepileptic drug that acts as a potassium-channel opener used for the adjunctive treatment of partial-onset seizures with or without secondary generalization in adults. In the European Union (EU), its use was restricted to those who have had an inadequate response to, or are intolerant of, other antiepileptics. Retigabine (ezogabine) was discontinued from US and European markets for commercial reasons in 2017.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL monograph for Retigabine (Ezogabine), just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.